

December 14, 2018

VIA SEDAR

Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Financial and Consumer Services Commission, New Brunswick
Nova Scotia Securities Commission
The Office of the Superintendent Securities –
Consumer, Corporate and Insurance Services Division – PEI
Office of the Superintendent of Securities, Newfoundland and Labrador

Dear Sirs/Mesdames,

**Re: Cardiol Therapeutics Inc. (the “Company”)
 Final Long Form Prospectus dated December 14, 2018**

We refer to the final long form prospectus of the Company dated December 14, 2018 (the “**Prospectus**”), relating to the distribution of Units.

We hereby consent to the references to our firm name on the second cover page of the Prospectus and under the heading “Legal Matters”. We also consent to the reference to and use of our name and opinion under the heading “Eligibility for Investment”.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our opinion referred to above or that are within our knowledge as a result of the services performed by us in connection with such opinion.

Yours truly,

(signed) “*Borden Ladner Gervais LLP*”